Anti-angiogenic compositions and methods of use

• US 7,820,193 B2
• Filed: 10/07/2004
• Issued: 10/26/2010
• Est. Priority Date: 07/19/1993
• Status: Expired due to Fees

• Current Assignee: Angiotech Pharmaceuticals Incorporated
• Original Assignee: Angiotech Pharmaceuticals Incorporated
• Inventors: Hunter, William L., Machan, Lindsay S., Arsenault, A. Larry
• Primary Examiner(s): Azpuru; Carlos A
• Application Number:
  US10/959,349
• Publication Number:
  US 20050123605A1
• Time in Patent Office: 2,210 Days
• Field of Search: None
• US Class Current: 424/426
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/136 having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/185 Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids hydroxamic acids A61K31/16; peroxy acids A61K31/327
• CPC Class Codes: A61K 31/203 Retinoic acids ; Salts thereof
• CPC Class Codes: A61K 31/335 having oxygen as the only ring hetero atom, e.g. fungichromin
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/426 1,3-Thiazoles
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/30 : Zinc; Compounds thereof
• CPC Class Codes: A61K 38/57 : from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61K 45/06 : Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0019 : Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0048 : Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/0051 : Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/14 : Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/1635 : obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/1641 : obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• CPC Class Codes: A61K 9/1647 : Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/1658 : Proteins, e.g. albumin, gelatin
• CPC Class Codes: A61K 9/5031 : obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5146 : obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
• CPC Class Codes: A61K 9/5153 : Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/7007 : Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61L 2300/416 : Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/606 : Coatings
• CPC Class Codes: A61L 2300/622 : Microcapsules
• CPC Class Codes: A61L 2430/36 : for embolization or occlusion, e.g. vaso-occlusive compositions or devices
• CPC Class Codes: A61L 31/10 : Macromolecular materials
• CPC Class Codes: A61L 31/145 : Hydrogels or hydrocolloids
• CPC Class Codes: A61L 31/16 : Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 1/04 : for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 : for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 : Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/02 : of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 19/02 : for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/14 : Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• CPC Class Codes: B82Y 5/00 : Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07C 233/64 : having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
• CPC Class Codes: C07K 14/811 : Serine protease (E.C. 3.4.21) inhibitors
• CPC Class Codes: C08L 2203/02 : for biomedical use
• CPC Class Codes: C08L 23/08 : Copolymers of ethene C08L23/16 takes precedence
• CPC Class Codes: C08L 23/0853 : Vinylacetate
• CPC Class Codes: C08L 2312/00 : Crosslinking
• CPC Class Codes: C08L 2666/04 : Macromolecular compounds according to groups C08L7/00 - C08L49/00, or C08L55/00 - C08L57/00; Derivatives thereof
• CPC Class Codes: C08L 2666/06 : Homopolymers or copolymers of unsaturated hydrocarbons; Derivatives thereof
• CPC Class Codes: C08L 2666/18 : Polyesters or polycarbonates according to C08L67/00 - C08L69/00; Derivatives thereof
• CPC Class Codes: C08L 29/04 : Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
• CPC Class Codes: C08L 67/04 : Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence
• CPC Class Codes: Y10S 977/773 : Nanoparticle, i.e. structure having three dimensions of 100 nm or less
• CPC Class Codes: Y10S 977/915 : Therapeutic or pharmaceutical composition

Abstract

The present invention is directed to a stent comprising

• • (a) a balloon expandable coronary stent; and
  • (b) paclitaxel, in an amount that when tested in a chick chorioallantoic membrane assay is anti-angiogenic.

Claims

1. A stent comprising

(a) a balloon expandable coronary stent;

and

(b) paclitaxel, in an amount that when tested in a chick chorioallantoic membrane assay is anti-angiogenic.

2. The stent of claim 1, wherein the amount of paclitaxel is 5 micrograms.

16. The stent of claim 1, 3, or 9, wherein the amount of paclitaxel is 10 μ

g.

17. The stent of claim 1, 3, or 9, wherein the amount of paclitaxel is 30 μ

g.

3. A stent comprising

(a) a balloon expandable coronary stent;

and

(b) paclitaxel or an analog thereof, in an amount that when tested in a chick chorioallantoic membrane assay is anti-angiogenic.

4. The stent of claim 3, wherein the amount of paclitaxel or an analog thereof is 5 micrograms.

5. A stent comprising

(a) a balloon expandable coronary stent and

(b) a composition comprising paclitaxel,

wherein the composition when tested in a chick chorioallantoic membrane assay is anti-angiogenic.

6. A vascular stent comprising

an expandable stent;

and

paclitaxel,

wherein the vascular stent contains paclitaxel in an effective amount which is capable of inhibiting angiogenesis in vivo.

7. The vascular stent of claim 6, wherein the vascular stent is capable of inhibiting angiogenesis in a CAM assay.

8. The vascular stent of claim 6, wherein the vascular stent is capable of inhibiting angiogenesis at a site of an angioplasty in a blood vessel.

9. A vascular stent prepared from components comprising:

(a) an expandable scaffold; and

(b) paclitaxel, in an amount that when tested in a chick chorioallantoic membrane assay is anti-angiogenic.

10. The vascular stent of claim 9, wherein the vascular stent is capable of inhibiting angiogenesis in vivo.

11. The vascular stent of claim 10, wherein the vascular stent is capable of inhibiting angiogenesis at a site of an angioplasty in a blood vessel.

12. The vascular stent of claim 10, wherein the amount of paclitaxel is 5 micrograms.

13. A vascular stent prepared from components comprising:

(a) a balloon expandable scaffold; and

(b) a composition comprising paclitaxel,

wherein the composition when tested in a chick chorioallantoic membrane assay is anti-angiogenic.

14. The vascular stent of claim 13, wherein the vascular stent is capable of inhibiting angiogenesis in vivo.

15. The vascular stent of claim 14, wherein the vascular stent is capable of inhibiting angiogenesis at a site of an angioplasty in a blood vessel.